市场调查报告书
商品编码
1271782
透皮给药系统市场——按类型、按应用、按最终用途和预测,2023 年至 2032 年Transdermal Drug Delivery Systems Market - By Type By Application By End-use & Forecast, 2023 - 2032 |
由于对非侵入式药物输送系统的需求不断增长,全球透皮药物输送系统市场预计从 2023 年到 2032 年将呈现适度的复合年增长率。
口服、局部和经皮等非侵入性给药方法无痛且副作用比侵入性程序少。 这些特性使这些系统多年来广受欢迎,推动了高度依赖自我管理的患者的采用,并由于降低了给药频率而提高了患者的依从性。
透皮给药系统市场按类型、应用、最终用途和地区划分。
按类型分,半固体型透皮贴剂的市场规模有望扩大至2032年。 喷雾剂等半固体透皮给药产品具有给药直接、副作用少等特点。 它还可以预先测量的剂量给药,以提高患者的疗效。 此外,软膏、凝胶和喷雾剂等各种半固体透皮製剂的可用性也将有利于到 2032 年采用。
在应用方面,心血管疾病领域在 2022 年已累积超过 19% 的市场份额。 由于全球心血管疾病 (CVD) 的高患病率,预计未来几年产品渗透率将增加。 据世界卫生组织称,心血管疾病是导致死亡的主要原因,每年在全世界造成约 1790 万人死亡。 此外,在治疗这些疾病时,越来越多的人接受无创给药装置,这将进一步加强透皮给药系统市场的增长前景。
到 2032 年,家庭保健领域的透皮给药系统的最终用途可能会达到公允价值。 透皮给药系统的最新创新促进了它们在家庭护理应用中的采用。 这些药物输送适合家庭使用,因为它们减少了与肠胃外给药相关的风险和不适。 从长远来看,对微创治疗的需求不断增长,预计也将有助于增加对该产品的需求。
预计到 2032 年,亚太地区的透皮给药系统市场将显着扩大。 不断增长的老年人口和对慢性病的易感性增加正在增加该地区对透皮给药系统的需求。 据世界卫生组织预测,到2040年,中国将有28%的人口超过60岁。 亚太地区是 Hisamitsu Pharmaceutical Co., Ltd. 等主要行业参与者的所在地,该公司不断致力于产品创新。 这也将对未来几年的整体市场动态产生积极影响。
Global Transdermal Drug Delivery System Market is expected to exhibit a decent CAGR from 2023 to 2032, owing to the rising demand for non-invasive drug delivery systems. Oral, topical, transdermal, and other non-invasive drug delivery methods are painless and demonstrate fewer side effects than invasive procedures. These attributes have added to the popularity of these systems over the years and boosted their adoption among patients with higher dependency on self-administration and improved patient compliance due to reduced dosing frequencies.
The overall transdermal drug delivery system market is categorized on the basis of type, application, end-use, and region.
Regarding the type, the transdermal drug delivery system market size from the semisolids segment is anticipated to garner commendable gains through 2032. Semisolid transdermal drug delivery products such as sprays enable direct drug delivery and have lesser side effects. Additionally, they help administer pre-measured doses in patients for better treatment. Moreover, the high availability of a wide range of semi-solid transdermal drug delivery products such as ointment, gels, sprays, and others will favor their adoption through 2032.
With respect to application, the cardiovascular diseases segment accumulated over 19% market share in 2022. High prevalence rate of cardiovascular disorders (CVDs) globally will increase product uptake in the forthcoming years. As per WHO, CVDs are a prominent cause of death, resulting in around 17.9 million mortalities across the globe annually. Moreover, the increased acceptance of non-invasive drug delivery devices for the treatment of these diseases will further create a strong growth outlook for the transdermal drug delivery system market.
Based on end-use, the transdermal drug delivery system industry from home care settings segment could record a decent valuation by 2032. Recent innovations in transdermal drug delivery systems have fostered their adoption in home care applications. These drug delivery systems reduce the risks and discomfort associated with the parenteral route of administration, making them suitable for home usage. This apart, the increasing demand for minimally invasive treatment will further contribute to strong product demand in the long run.
Asia Pacific transdermal drug delivery system market is poised to expand substantially through 2032. Rising geriatric population and its higher susceptibility to chronic disorders have increased the demand for transdermal drug delivery systems in the region. According to WHO, 28% of the total population in China will be above 60 years by 2040. Asia Pacific is also home to key industry players such as Hisamitsu Pharmaceutical Co., Inc. and others constantly indulged in product innovations. This will also have a positive impact on the overall market dynamics in the coming years.